A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
В этом разделе статьи показаны на английском.
A pharma giant is moving past one patent cliff — but another is already looming
Лента Trade News, 2026-10-30: Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks. Первоисточник — оригинал CNBC Top News (cnbc.com).
